Bicycle Therapeutics (NASDAQ:BCYC) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10, Briefing.com reports. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.16) earnings per share.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock traded down $0.06 during midday trading on Friday, reaching $10.97. The stock had a trading volume of 275,772 shares, compared to its average volume of 301,484. The firm's fifty day simple moving average is $13.19 and its two-hundred day simple moving average is $19.32. The firm has a market cap of $757.43 million, a price-to-earnings ratio of -3.33 and a beta of 0.93. Bicycle Therapeutics has a twelve month low of $10.81 and a twelve month high of $28.67.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now owns 32,146 shares of the company's stock, valued at $482,190. This trade represents a 7.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 27,677 shares of company stock valued at $392,413 in the last quarter. Company insiders own 8.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BCYC. Needham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. HC Wainwright restated a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. Royal Bank of Canada restated an "outperform" rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. B. Riley decreased their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Finally, JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.